管理印度尼西亚的牛奶蛋白过敏:从私人付款人的角度对低致敏性牛奶配方奶粉的成本效益分析。

IF 2.3 Q2 ECONOMICS
Journal of Health Economics and Outcomes Research Pub Date : 2022-09-07 eCollection Date: 2022-01-01 DOI:10.36469/001c.36407
Ana Teresa Paquete, Rui Martins, Mark P Connolly, Badriul Hegar, Zakiudin Munasir, Stephanus Stephanus
{"title":"管理印度尼西亚的牛奶蛋白过敏:从私人付款人的角度对低致敏性牛奶配方奶粉的成本效益分析。","authors":"Ana Teresa Paquete, Rui Martins, Mark P Connolly, Badriul Hegar, Zakiudin Munasir, Stephanus Stephanus","doi":"10.36469/001c.36407","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Cow's milk protein allergy is very common in early childhood. Extensively hydrolyzed formulas are recommended in the first-line management of cow's milk protein allergy in non-breastfed children. Choice of formulas should be informed by efficacy and cost data. <b>Objectives:</b> This study aims to compare the cost-effectiveness of extensively hydrolyzed casein formula with <i>Lacticaseibacillus rhamnosus</i> Gorbach Goldin (EHCF+LGG), extensively hydrolyzed whey formula (EHWF), amino acid formula, and soy formula in the first-line management of cow's milk protein allergy in non-breastfed children in Indonesia. <b>Methods:</b> A trial-based decision analytic cohort model was adapted to simulate the occurrence of cow's milk protein allergy symptoms or being symptom free. The model was based on a prospective nonrandomized study that followed up children for 36 months. Costs and health consequences were discounted at 3% annually. Resources required to manage cow's milk protein allergy and unit costs for clinical appointments and exams were based on a panel of 15 clinicians, from a private payers' perspective. Other unit costs were based on publicly available national data. Results were reported as cost per additional child free from allergic manifestations or per additional immunotolerant child at 3 years, and per life-years under the same conditions. Uncertainty was assessed using deterministic and probabilistic sensitivity analysis. <b>Results:</b> Children receiving EHCF+LGG were associated with more symptom-free time, a higher probability of cow's milk tolerance at 3 years, and lower healthcare resources and transportation use when compared with children receiving other formulas (with 38%-49% lower costs). Formula costs were lower for soy, but EHCF+LGG was predicted to save 9% and 54% of overall costs compared with extensively hydrolyzed whey formula and amino acid formula, respectively. Results were robust to sensitivity analyses. <b>Conclusion:</b> Use of EHCF+LGG resulted in more symptom-free time and the highest 3-year probability of cow's milk tolerance. It also led to healthcare resource and transportation savings when compared with other hypoallergenic milk formulas. Soy formula remained an alternative if formula price represents a major constraint.</p>","PeriodicalId":16012,"journal":{"name":"Journal of Health Economics and Outcomes Research","volume":"9 2","pages":"77-85"},"PeriodicalIF":2.3000,"publicationDate":"2022-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452772/pdf/","citationCount":"0","resultStr":"{\"title\":\"Managing Cow's Milk Protein Allergy in Indonesia: A Cost-effectiveness Analysis of Hypoallergenic Milk Formulas from the Private Payers' Perspective.\",\"authors\":\"Ana Teresa Paquete, Rui Martins, Mark P Connolly, Badriul Hegar, Zakiudin Munasir, Stephanus Stephanus\",\"doi\":\"10.36469/001c.36407\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Cow's milk protein allergy is very common in early childhood. Extensively hydrolyzed formulas are recommended in the first-line management of cow's milk protein allergy in non-breastfed children. Choice of formulas should be informed by efficacy and cost data. <b>Objectives:</b> This study aims to compare the cost-effectiveness of extensively hydrolyzed casein formula with <i>Lacticaseibacillus rhamnosus</i> Gorbach Goldin (EHCF+LGG), extensively hydrolyzed whey formula (EHWF), amino acid formula, and soy formula in the first-line management of cow's milk protein allergy in non-breastfed children in Indonesia. <b>Methods:</b> A trial-based decision analytic cohort model was adapted to simulate the occurrence of cow's milk protein allergy symptoms or being symptom free. The model was based on a prospective nonrandomized study that followed up children for 36 months. Costs and health consequences were discounted at 3% annually. Resources required to manage cow's milk protein allergy and unit costs for clinical appointments and exams were based on a panel of 15 clinicians, from a private payers' perspective. Other unit costs were based on publicly available national data. Results were reported as cost per additional child free from allergic manifestations or per additional immunotolerant child at 3 years, and per life-years under the same conditions. Uncertainty was assessed using deterministic and probabilistic sensitivity analysis. <b>Results:</b> Children receiving EHCF+LGG were associated with more symptom-free time, a higher probability of cow's milk tolerance at 3 years, and lower healthcare resources and transportation use when compared with children receiving other formulas (with 38%-49% lower costs). Formula costs were lower for soy, but EHCF+LGG was predicted to save 9% and 54% of overall costs compared with extensively hydrolyzed whey formula and amino acid formula, respectively. Results were robust to sensitivity analyses. <b>Conclusion:</b> Use of EHCF+LGG resulted in more symptom-free time and the highest 3-year probability of cow's milk tolerance. It also led to healthcare resource and transportation savings when compared with other hypoallergenic milk formulas. Soy formula remained an alternative if formula price represents a major constraint.</p>\",\"PeriodicalId\":16012,\"journal\":{\"name\":\"Journal of Health Economics and Outcomes Research\",\"volume\":\"9 2\",\"pages\":\"77-85\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2022-09-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452772/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Health Economics and Outcomes Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36469/001c.36407\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ECONOMICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Health Economics and Outcomes Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36469/001c.36407","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

摘要

背景:牛奶蛋白过敏在儿童早期很常见。广泛水解配方奶粉被推荐用于非母乳喂养儿童牛奶蛋白过敏的一线治疗。配方的选择应根据疗效和成本数据。目的:本研究旨在比较广泛水解酪蛋白配方奶粉与鼠李糖乳杆菌戈尔巴赫-戈尔丁(EHCF+LGG)、广泛水解乳清配方奶粉(EHWF)、氨基酸配方奶粉和大豆配方奶粉在印度尼西亚非母乳喂养儿童牛奶蛋白过敏一线治疗中的成本效益。方法:采用基于试验的决策分析队列模型来模拟牛奶蛋白过敏症状的发生或无症状的发生。该模型基于一项前瞻性非随机研究,对儿童进行了36个月的随访。成本和健康后果每年按3%贴现。从私人支付者的角度来看,管理牛奶蛋白过敏所需的资源以及临床预约和检查的单位成本是基于一个由15名临床医生组成的小组。其他单位费用是根据公开的国家数据计算的。结果报告为每增加一个没有过敏表现的儿童的费用,或每增加一名免疫耐受儿童在3岁时的费用,以及在相同条件下的每生命年的费用。使用确定性和概率敏感性分析来评估不确定性。结果:与接受其他配方奶粉的儿童相比,接受EHCF+LGG的儿童有更多的无症状时间,3岁时耐牛奶的概率更高,医疗资源和交通使用更少(成本降低38%-49%)。大豆配方奶粉的成本较低,但与广泛水解的乳清配方奶粉和氨基酸配方奶粉相比,EHCF+LGG预计分别节省9%和54%的总成本。结果对敏感性分析具有稳健性。结论:使用EHCF+LGG可获得更多的无症状时间和最高的3年耐奶性概率。与其他低过敏性配方奶粉相比,它还节省了医疗资源和运输费用。如果配方奶粉价格是一个主要制约因素,大豆配方奶粉仍然是一种替代品。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Managing Cow's Milk Protein Allergy in Indonesia: A Cost-effectiveness Analysis of Hypoallergenic Milk Formulas from the Private Payers' Perspective.

Managing Cow's Milk Protein Allergy in Indonesia: A Cost-effectiveness Analysis of Hypoallergenic Milk Formulas from the Private Payers' Perspective.

Managing Cow's Milk Protein Allergy in Indonesia: A Cost-effectiveness Analysis of Hypoallergenic Milk Formulas from the Private Payers' Perspective.

Background: Cow's milk protein allergy is very common in early childhood. Extensively hydrolyzed formulas are recommended in the first-line management of cow's milk protein allergy in non-breastfed children. Choice of formulas should be informed by efficacy and cost data. Objectives: This study aims to compare the cost-effectiveness of extensively hydrolyzed casein formula with Lacticaseibacillus rhamnosus Gorbach Goldin (EHCF+LGG), extensively hydrolyzed whey formula (EHWF), amino acid formula, and soy formula in the first-line management of cow's milk protein allergy in non-breastfed children in Indonesia. Methods: A trial-based decision analytic cohort model was adapted to simulate the occurrence of cow's milk protein allergy symptoms or being symptom free. The model was based on a prospective nonrandomized study that followed up children for 36 months. Costs and health consequences were discounted at 3% annually. Resources required to manage cow's milk protein allergy and unit costs for clinical appointments and exams were based on a panel of 15 clinicians, from a private payers' perspective. Other unit costs were based on publicly available national data. Results were reported as cost per additional child free from allergic manifestations or per additional immunotolerant child at 3 years, and per life-years under the same conditions. Uncertainty was assessed using deterministic and probabilistic sensitivity analysis. Results: Children receiving EHCF+LGG were associated with more symptom-free time, a higher probability of cow's milk tolerance at 3 years, and lower healthcare resources and transportation use when compared with children receiving other formulas (with 38%-49% lower costs). Formula costs were lower for soy, but EHCF+LGG was predicted to save 9% and 54% of overall costs compared with extensively hydrolyzed whey formula and amino acid formula, respectively. Results were robust to sensitivity analyses. Conclusion: Use of EHCF+LGG resulted in more symptom-free time and the highest 3-year probability of cow's milk tolerance. It also led to healthcare resource and transportation savings when compared with other hypoallergenic milk formulas. Soy formula remained an alternative if formula price represents a major constraint.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.00
自引率
0.00%
发文量
55
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信